Giannis S. Mountzios, MD, of Henry Dunant Hospital Center, discusses findings from a post hoc analysis of the phase III DeLLphi-304 trial, which examined the intracranial efficacy of tarlatamab vs chemotherapy as second-line therapy for small cell lung cancer (SCLC) (Abstract 8006).
Mark A. Dickson, MD, of Memorial Sloan Kettering Cancer Center, presents findings from SARC041, a phase III randomized double-blind study of abemaciclib vs placebo in patients with dedifferentiated liposarcoma; patients who received abemaciclib experienced a statistically significant improvement in progression-free survival (Abstract LBA2).
Suneel Kamath, MD, of Cleveland Clinic, discusses a study that found tissue tumor mutation burden (TMB) was a stronger predictor of immunotherapy outcomes than blood-based circulating tumor DNA testing, with high tissue TMB associated with a longer time to treatment failure (Abstract 2580).
Laura Alder, MD, of Duke University Medical Center, highlights emerging data discussed in the meeting’s oral abstract session on small cell lung cancer, including increased toxicity without efficacy benefit from concurrent chemoradiation and immunotherapy, the intracranial activity of tarlatamab-dlle, and early data for a SEZ6-targeting antibody-drug conjugate.
Noelle Cloven, MD, of Texas Oncology, discusses the actively recruiting RAINFOL-03 (ENGOT-EN-31/GOG-3128) study, a global, phase III, open-label, randomized study of rinatabart sesutecan vs investigator’s choice of chemotherapy in patients with endometrial cancer after receipt of platinum-based chemotherapy and PD-L1 inhibition (Abstract TPS5646).
Joel W. Neal, MD, PhD, of Stanford Cancer Institute, discusses updated overall survival data from cohort C of the CHRYSALIS-2 trial, which looked at first-line amivantamab plus lazertinib in previously untreated patients with atypical EGFR-mutated advanced non–small cell lung cancer (NSCLC) (Abstract 8501).
